{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035437","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.872719+00:00","generated_at":"2026-06-21T04:58:11.514720+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma","bullets":["In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.","NXC-201 showed 85% ORR and 71% CR/sCR in 20 relapsed/refractory multiple myeloma patients; 100% ORR and organ response in AL amyloidosis.","Zero neurotoxicity observed; median CRS duration of 2 days at therapeutic dose, supporting potential outpatient use.","Financial terms: $1.5M upfront, $50k annual fee, mid-single digit royalties, up to $20M sales milestones.","Formed wholly-owned subsidiary Nexcella to develop NXC-201; expects minimal impact on Immix financials as Nexcella independently financed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035437","json":"https://secwatch.observer/filing/0001493152-22-035437.json","markdown":"https://secwatch.observer/filing/0001493152-22-035437.md","text":"https://secwatch.observer/filing/0001493152-22-035437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/0001493152-22-035437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:58:11.514720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db83637b4fbb81938465a30bcd3ff4ec84a9095e","claim":"Immix Biopharma, Inc. entered into Research and License Agreement with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. valued at $1,500,000 (effective 2022-12-08).","evidence_excerpt":"On December 8, 2022, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.) (“Nexcella”), a wholly-owned subsidiary of Immix Biopharma, Inc. (the “Company”) entered into a Research and License Agreement (the “Agreement”) with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. (collectively, the “Licensors”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222035437/0001493152-22-035437-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd."},{"label":"Value","value":"$1,500,000"},{"label":"Effective","value":"2022-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}